NCT07777640Completed
Intra-Ovarian PRP Compared With Gonadotropin for Ovarian Response in Letrozole-Resistant PCOS
Effect of Intra-Ovarian Injection of Autologous Platelet Rich Plasma Compared to Gonadotropin on Ovarian Response in Letrozole Resistant Polycystic Ovary Syndrome
Source: ClinicalTrials.gov · Last updated 20 Aug 2026
Brief summary (registry, in English)
The goal of this randomized clinical trial is to compare autologous platelet-rich plasma (PRP) with gonadotropin for improving ovarian response in women with letrozole-resistant polycystic ovary syndrome (PCOS). Researchers will compare the two treatments to assess ovarian response, ovulation rates, and pregnancy rates. Participants will be randomly assigned to receive either intra-ovarian autologous PRP or gonadotropin treatment and will be followed for three consecutive cycles.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 11 Aug 2026
- Start date
- 1 Jun 2025
- Primary completion date
- 20 May 2026
- Lead sponsor
- Bangladesh Medical University
- NCT number
- NCT07777640
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 1 Jun 2025 to the primary completion date, 20 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient not fit for surgery.
Other illness
- Patients with uncontrolled endocrine disorders (e.g., thyroid dysfunction, hyperprolactinemia).
- Hypersensitivity to gonadotropin.
Lab values
- Any contraindication to platelet-rich plasma (PRP) therapy (coagulation disorder or current use of anticoagulant).
Other
- Body Mass Index (BMI) \<18.5 kg/m² or ≥30 kg/m².
- Presence of other causes of infertility (e.g., endometriosis, tubal factor, severe male factor infertility).
Who the study is looking for
- Women aged 18-35 years diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam criteria.
- Primary or secondary subfertility.
- Patients with a history of letrozole resistance (failure to ovulate with standard dose of letrozole).
Age in the registry: 18 years to 35 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Reproductive Endocrinology and Infertility, Bangladesh Medical University Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.